Every 10-Q that CANNABIS BIOSCI INTL HLDG (CBIH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CBIH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBIH filings page.
Cannabis Bioscience International Holdings, Inc. reported another quarterly loss and flagged substantial doubt about its ability to continue as a going concern for the period ended February 28, 2026.
Revenue for the nine months was $88,671, sharply lower than $268,066 a year earlier, mainly from reduced clinical trial contracts. Operating expenses were $330,903, leading to a nine-month net loss of $303,546.
The balance sheet is highly strained: cash was only $90, total liabilities were $1,468,674, and stockholders’ deficiency was $1,467,130. Working capital was negative $1,217,630, and accumulated deficit reached $6,186,448. The company relies on high-interest debt, related-party financing and has several loans in arrears or default while still having over 11.6 billion common shares outstanding and no proceeds yet from its previously declared effective equity offering.
Cannabis Bioscience International Holdings, Inc. reported another weak quarter, with revenues for the three months ended November 30, 2025 falling to $53,266 from $74,248 a year earlier, mainly from lower clinical trial activity.
Operating expenses rose to $138,643, driven largely by higher professional fees, pushing the quarterly net loss to $116,966 versus a loss of $79,528 in the prior-year quarter. For the six-month period, revenue dropped sharply to $77,466 from $253,135, while the net loss widened to $199,612.
The balance sheet remains strained: cash was only $132, total assets were $22,131, and there was a working capital deficit of $1,113,695 and stockholders’ deficiency of $1,363,195 as of November 30, 2025. Management discloses substantial doubt about the company’s ability to continue as a going concern, and it is relying on related-party and SBA debt while seeking additional financing. On December 31, 2025, the company also terminated its Pharmacology University education business.
Cannabis Bioscience International Holdings (CBIH) reported Q1 results for the quarter ended August 31, 2025. Revenue fell to $24,200 from $178,887 a year ago, driven mainly by fewer clinical trial contracts. Gross profit was $16,057, with operating expenses of $90,841, leading to an operating loss of $74,784. After other items, including a $29,322 gain from the change in derivative liabilities and $17,368 of interest expense, net loss was $82,645 (vs. $76,305 last year).
Liquidity remains tight. Cash was $223 at quarter-end, and the company disclosed a working capital deficit of $996,728 and a stockholders’ deficiency of $(1,246,228), with total liabilities of $1,265,170. Management states there is substantial doubt about the company’s ability to continue as a going concern. Two customers represented 95% of quarterly revenue. The company noted no sales under its effective S-1 to date. Shares outstanding were 11,626,749,347 as of October 22, 2025.